Finanza

Discussioni Tecnici Previsione Stagionalità

Utile netto su Prelude Therapeutics Incorporated.

Dati annuali

2019

2020

2021

2022

2023

TTM

‪‪−140,00 M‬‬

‪‪−105,00 M‬‬

‪‪−70,00 M‬‬

‪‪−35,00 M‬‬

‪0,00‬

Periodo

Valore

Variazione

Variazione %

TTM

‪‪−131,52 M‬‬

‪‪−9,69 M‬‬

‪−7,95‬%

2023

‪‪−121,83 M‬‬

‪‪−6,39 M‬‬

‪−5,54‬%

2022

‪‪−115,44 M‬‬

‪‪−3,74 M‬‬

‪−3,35‬%

2021

‪‪−111,69 M‬‬

‪‪−54,77 M‬‬

‪−96,20‬%

2020

‪‪−56,93 M‬‬

‪‪−29,36 M‬‬

‪−106,49‬%

2019

‪‪−27,57 M‬‬

‪‪−12,89 M‬‬

‪−87,81‬%

Dati trimestrali

Q4 '19

Q1 '20

Q2 '20

Q3 '20

Q4 '20

Q1 '21

Q2 '21

Q3 '21

Q4 '21

Q1 '22

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

Q2 '24

Q3 '24

‪‪−36,00 M‬‬

‪‪−27,00 M‬‬

‪‪−18,00 M‬‬

‪‪−9,00 M‬‬

‪0,00‬

Periodo

Valore

Variazione

Variazione %

Q3 '24

‪‪−32,27 M‬‬

+‪‪2,47 M‬‬

+‪7,11‬%

Q2 '24

‪‪−34,74 M‬‬

‪‪−3,31 M‬‬

‪−10,53‬%

Q1 '24

‪‪−31,43 M‬‬

+‪‪1,64 M‬‬

+‪4,97‬%

Q4 '23

‪‪−33,08 M‬‬

‪‪−2,47 M‬‬

‪−8,06‬%

Q3 '23

‪‪−30,61 M‬‬

‪‪−177,00 K‬‬

‪−0,58‬%

Q2 '23

‪‪−30,43 M‬‬

‪‪−2,71 M‬‬

‪−9,79‬%

Q1 '23

‪‪−27,72 M‬‬

+‪‪923,00 K‬‬

+‪3,22‬%

Q4 '22

‪‪−28,64 M‬‬

+‪‪1,32 M‬‬

+‪4,40‬%

Q3 '22

Q2 '22

Q1 '22

Q4 '21

Q3 '21

Q2 '21

Q1 '21

Q4 '20

Q3 '20

Q2 '20

Q1 '20

Q4 '19